-
Genomic Profiling of Pediatric Tumors by Cell Free DNA Sequencing
Study
EGAS50000000072
-
Identifying mutations in patient-derived melanoma DCC lines
Study
EGAS50000001225
-
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma
Study
EGAS50000001217
-
Whole genome bisulfite sequencing of prostate cancer samples upon oral pimonidazole administration
Study
EGAS50000000069
-
MediMer: A versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection
Study
EGAS50000000065
-
Metabolic requirements of the metastasis-initiating tumour cell population using oral squamous cell carcinoma (OSCC) as a model system
Study
EGAS00001004765
-
Whole Exome Sequencing of Multiple Myeloma Patients
Study
EGAS50000000394
-
Cerebrospinal fluid cfDNA sequencing for classification of central nervous system glioma
Study
EGAS50000000060
-
RNA-Seq data from tumor samples collected from 12 UTSW translocation renal cell carcinoma (tRCC) patients.
Study
EGAS50000000127
-
Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient
Study
EGAS50000000102
-
Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma.
Study
EGAS00001004320
-
Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis
Study
EGAS50000000135
-
Transcriptome of CD4+ T cells and CD8+ T cells in glioblastoma multiforme
Study
EGAS50000000156
-
Co-culture experiment (hashed samples)
Study
EGAS50000001252
-
Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high risk lineage ambiguous leukemia
Study
EGAS50000001255
-
Capmatinib shows superior efficacy for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy
Study
EGAS50000000137
-
Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway
Study
EGAS50000000136
-
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Study
EGAS50000000168
-
Karyotype Evolution in Response to Chemoradiotherapy and Upon Recurrence of Esophageal Adenocarcinomas
Study
EGAS00001007711
-
Comprehensive spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer
Study
EGAS50000000220
-
Single-cell atlas of penile cancer reveals TP53 mutations as driver for an aggressive phenotype, irrespective of HPV status, and provides clues for treatment personalization
Study
EGAS50000000217
-
Clonal Evolution and Blastic Plasmacytoid Dendritic Cell Neoplasm - Two Cases
Study
EGAS50000000214
-
Dynamics of checkpoint receptors in γδ T cell subsets are associated with clinical responses during anti-PD-1 immunotherapies
Study
EGAS50000001270
-
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations
Study
EGAS50000001272
-
Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease
Study
EGAS50000000215
-
Patient-Derived Follicular Lymphoma Spheroids recapitulate lymph node signaling and immune profile, uncovering galectin-9 as a novel immunotherapeutic target
Study
EGAS50000000233
-
Neversmoker lung adenocarcinoma
Study
EGAS50000000232
-
Genomic profiles associated with response to immunotherapy in adolescent and young adult patients with melanoma
Study
EGAS50000000238
-
Medulloblastoma RNAseq
Study
EGAS50000000262
-
Accelerated single cell seeding in relapsed multiple myeloma
Study
EGAS00001004404
-
Whole Exome Sequencing
Study
EGAS50000000259
-
Medulloblastoma WES
Study
EGAS50000000261
-
PRADO trial - Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Study
EGAS50000000268
-
A neoadjuvant, phase II trial demonstrates efficacy and tolerability of Talimogene laherparepvec in cutaneous basal cell carcinoma (NeoBCC trial)
Study
EGAS50000000252
-
Clonal heterogeneity leads to secondary resistance in a melanoma patient after adoptive cell therapy with tumor-infiltrating lymphocytes
Study
EGAS50000000279
-
A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600 mutated melanoma
Study
EGAS00001007709
-
Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma
Study
EGAS50000000287
-
WHOLE GENOME SEQUENCING OF CLEAR CELL RENAL CELL CARCINOMA IN VHL PATIENT
Study
EGAS50000000295
-
ScRNA-seq of human kidney immune cells of patients with ANCA-associated glomerulonephritis, Lupus Nephritis against a "healthy" nephrectomy control
Study
EGAS50000000159
-
Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma
Study
EGAS00001004430
-
Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation
Study
EGAS50000000302
-
WES in HCCOs with varying Doxorubicin resistance
Study
EGAS50000000043
-
Tracing tumor evolution and heterogeneity of pleomorphic carcinoma of the lung
Study
EGAS50000000314
-
Whole-genome sequencing of primary mediastinal large B-cell lymphoma
Study
EGAS50000000340
-
ROBUST (NCT02285062)
Study
EGAS50000000333
-
Single cell transcriptomic profiles of advanced melanoma patients treated with checkpoint inhibitor immunotherapy
Study
EGAS50000000339
-
WES of paired gDNAs and PPGL tumor DNA from patients with CCHD-PPGL.
Study
EGAS50000000815
-
A single-cell multi-omic atlas of nodal B-cell non-Hodgkin lymphomas
Study
EGAS50000000342
-
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
Study
EGAS00001004288
-
Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution
Study
EGAS50000000345